{"id":239839,"date":"2025-12-18T20:31:09","date_gmt":"2025-12-18T20:31:09","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/239839\/"},"modified":"2025-12-18T20:31:09","modified_gmt":"2025-12-18T20:31:09","slug":"medicare-enrollees-to-pay-50-less-for-some-drugs-in-2025-report-says","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/239839\/","title":{"rendered":"Medicare enrollees to pay 50% less for some drugs in 2025, report says"},"content":{"rendered":"<ul data-testid=\"Summary\" class=\"summary-module__summary__QjADA\">\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">AARP study looks at first 10 drugs negotiated under IRA<\/li>\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">Finds 7 of the drugs will cost under $100 in 2026<\/li>\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">Analyzes plans in California, Florida, Texas, New York, Pennsylvania<\/li>\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">Savings stem from lower coinsurance based on negotiated prices<\/li>\n<\/ul>\n<p>WASHINGTON, Dec 18 (Reuters) &#8211; Americans enrolled in Medicare will pay about 50% less out of pocket in 2026 for some drugs including Pfizer <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/PFE.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(PFE.N), opens new tab<\/a> and Bristol Myers Squibb&#8217;s <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/BMY.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(BMY.N), opens new tab<\/a> blood thinner Eliquis and Merck &amp; Co&#8217;s <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/MRK.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(MRK.N), opens new tab<\/a> diabetes drug Januvia, a study in the five most populous U.S. states suggested.<\/p>\n<p>Medicare negotiated prices kick in next month for 10 drugs, a first for former President Joe Biden&#8217;s signature Inflation Reduction Act of 2022. Medicare covers over 67 million people aged 65 and older or with disabilities.<\/p>\n<p data-testid=\"promo-box\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__promo-box__hVl8h\"> Sign up  <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/medicare-enrollees-pay-50-less-some-drugs-2025-report-says-2025-12-18\/undefined?location=article-paragraph&amp;redirectUrl=%2Fbusiness%2Fhealthcare-pharmaceuticals%2Fmedicare-enrollees-pay-50-less-some-drugs-2025-report-says-2025-12-18%2F\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">here.<\/a><\/p>\n<p>The report estimates that out-of-pocket costs for the 10 drugs will fall nearly 50% in 2026 versus 2025 in all 56 stand-alone prescription drug plans in California, Florida, Texas, New York, and Pennsylvania, the analysis of public Medicare spending data found.<\/p>\n<p>Seven of the drugs are expected to cost below $100 per month by 2026, up from two under that amount in 2025.<\/p>\n<p>However, patients taking the three priciest drugs; Amgen&#8217;s <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/AMGN.O\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(AMGN.O), opens new tab<\/a> rheumatoid arthritis treatment Enbrel, AbbVie&#8217;s <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/ABBV.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(ABBV.N), opens new tab<\/a> leukemia therapy Imbruvica, and Johnson &amp; Johnson&#8217;s <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/JNJ.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(JNJ.N), opens new tab<\/a> Crohn&#8217;s disease medicine Stelara, will still face higher out-of-pocket costs ranging from around $600 to $2,800 a month.<\/p>\n<p>The law also has a new lower Medicare out-of-pocket drug spending cap, set at $2,100 per year in 2026.<\/p>\n<p>Out-of-pocket costs include co-pays, flat fees, and coinsurance, which is a percentage of the drug price. Savings stem mainly from lower coinsurance tied to negotiated prices, and some co-pay changes related in particular to lower insulin prices.<\/p>\n<p>AARP, the lobbying group for older Americans, said further research is needed to determine whether the findings extend to the broader Medicare market. The study noted considerable variation in savings between plans.<\/p>\n<p>The other drugs included in the first round of negotiations are J&amp;J&#8217;s Eliquis rival Xarelto, Boehringer Ingelheim and Eli Lilly&#8217;s <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/LLY.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(LLY.N), opens new tab<\/a> diabetes drug Jardiance, and insulin from Novo Nordisk <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/NOVOb.CO\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(NOVOb.CO), opens new tab<\/a>.<\/p>\n<p>The drugs are used by nearly 9 million people on Medicare prescription drug plans who paid as much as $6,500 per year for these prescriptions before the IRA&#8217;s passage. Four of the drugs were not covered by all Medicare drug plans in 2025 but will be universally covered in 2026 under IRA mandates.<\/p>\n<p>The U.S. Centers for Medicare &amp; Medicaid Services estimates the negotiated prices could save enrollees a collective $1.5 billion in out-of-pocket expenses in 2026.<\/p>\n<p data-testid=\"SignOff\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__extra_small__8Buss body-module__full_width__kCIGb body-module__extra_small_body__Bfz20 sign-off-module__text__LQAMP\">Reporting by Ahmed Aboulenein; editing by Caroline Humer and Nick Zieminski<\/p>\n<p data-testid=\"Body\" dir=\"ltr\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__element__5eCce article-body-module__trust-badge__5mS3f\">Our Standards: <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.thomsonreuters.com\/en\/about-us\/trust-principles.html\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__medium__2Rl30 text-module__small__sph8i link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n<p><a href=\"https:\/\/www.reutersagency.com\/en\/licensereuterscontent\/?utm_medium=rcom-article-media&amp;utm_campaign=rcom-rcp-lead\" target=\"_blank\" dir=\"ltr\" class=\"button-module__link__A3sD0 button-module__secondary__70gBu button-module__round__QDFgq button-module__w_auto__Sem-F\" data-testid=\"LicenceContentButton\" rel=\"nofollow noopener\">Purchase Licensing Rights<\/a><a data-testid=\"AuthorBioImageLink\" class=\"author-bio-module__author-image__jcaG3\" href=\"https:\/\/www.reuters.com\/authors\/ahmed-aboulenein\/\" referrerpolicy=\"no-referrer-when-downgrade\" tabindex=\"-1\" rel=\"nofollow noopener\" target=\"_blank\"><\/a><\/p>\n<p data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__extra_small__8Buss body-module__base__o--Cl body-module__extra_small_body__Bfz20 author-bio-module__description__9ynkB\">Washington-based correspondent covering U.S. healthcare and pharmaceutical policy with a focus on the Department of Health and Human Services and the agencies it oversees such as the Food and Drug Administration, previously based in Iraq and Egypt.<\/p>\n","protected":false},"excerpt":{"rendered":"AARP study looks at first 10 drugs negotiated under IRA Finds 7 of the drugs will cost under&hellip;\n","protected":false},"author":2,"featured_media":239840,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[82519,82531,84147,87219,18,45748,126548,87209,135,87211,19,17,462,82524,88229,82508,126547,88232,107,83127],"class_list":{"0":"post-239839","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-amers","9":"tag-destousbsm","10":"tag-destousdnm","11":"tag-destoushem","12":"tag-eire","13":"tag-gen","14":"tag-hcpol","15":"tag-hea","16":"tag-health","17":"tag-heca","18":"tag-ie","19":"tag-ireland","20":"tag-medication","21":"tag-namer","22":"tag-phmr","23":"tag-pol","24":"tag-rhpigovernment-health-policy","25":"tag-topicpharma-healthcare-policy-regulation","26":"tag-us","27":"tag-wash"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115742473119437520","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/239839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=239839"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/239839\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/239840"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=239839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=239839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=239839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}